EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease

Ayinula Tuohetali, Bei Chen, Qinwei Xu, Jiang Zhu, Zhenping Zhang, Xia Chen, Yixueying Ma, Kadierya Kuerban, Kalibixiati Aimulajiang, Huijing Gao iD

PLOS Neglected Tropical Diseases · 2026

DOI: 10.1371/journal.pntd.0014483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2026. Verfasst von Ayinula Tuohetali und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Department of Pharmacy, The First Affiliat…. Hauptthemen laut MEDLINE: Echinococcosis, Hepatic, Lactic Acid, Anthelmintics, Polyglycolic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Programme of Xinjiang Uygur Autonomous Region, “Tianshan Talent” Program for Training High-level Talents in Medicine and Healthcare, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Harmine (HM), a bioactive alkaloid, exhibits remarkable antiparasitic potency. Nevertheless, its translational potential is substantially constrained by neurotoxicity, necessitating the development of safer analogs. H-2-168, a rationally designed derivative synthesized via targeted structural modifications of the HM core, has emerged as a leading candidate for further therapeutic exploration due to its favorable pharmacological profile. To optimize its pharmacokinetic properties and enhance treatment efficacy, this study reports the fabrication of H-2-168-loaded poly (lactic - co - glycolic acid) (PLGA) nanoparticles (H8-PLGA-NPs). Results demonstrated that H8-PLGA-NPs exhibited uniform spherical morphology with an average diameter of 198 nm (PDI = 0.15) and a high drug encapsulation efficiency of 88.6%. Following 30-day oral administration (100 mg/kg/day), H8-PLGA-NPs demonstrated significantly enhanced anthelmintic efficacy and tissue regenerative capacity compared to free H-2-168, while effectively ameliorating inflammatory responses and hepatic fibrosis progression. Notably, systemic toxicity was substantially reduced, particularly hepatotoxicity and cytotoxicity. This study substantiates that PLGA-based nanocarriers markedly improve the therapeutic outcomes of H-2-168 against cystic echinococcosis (CE) through optimized drug encapsulation and delivery efficiency, thereby proposing a promising therapeutic strategy for CE management. Nevertheless, comprehensive investigations into the long-term biosafety profiles of these nanoparticles and optimal dosing regimens warrant further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Echinococcosis, HepaticLactic AcidAnthelminticsPolyglycolic AcidAnimalsPolylactic Acid-Polyglycolic Acid CopolymerNanoparticlesMiceHumansMaleDrug CarriersLiverAdministration, OralFemale

Substanzen

Polylactic Acid-Polyglycolic Acid CopolymerLactic AcidAnthelminticsDrug CarriersPolyglycolic Acid

Autor:innen und Institutionen

  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Department of Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, China.
  • Department of Abdominal Surgery, The Third People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
  • Clinical Medicine Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

ORCID-Profile: Huijing Gao

Förderung

  • Key R&D Programme of Xinjiang Uygur Autonomous Region
  • “Tianshan Talent” Program for Training High-level Talents in Medicine and Healthcare
  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund
  • 2023 Clinical Pharmacy Research Fund of Chinese Society of Clinical Pharmacy, China International Medical Exchange Foundation
  • Research Fund of Xinjiang Uygur Autonomous Region Pharmaceutical Association
  • Xinjiang Agricultural University Graduate Research and Innovation Fund

Zitieren

APA

Tuohetali, A., Chen, B., Xu, Q., Zhu, J., Zhang, Z., Chen, X., Ma, Y., Kuerban, K., Aimulajiang, K., & Gao, H. (2026). PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0014483

Vancouver

Tuohetali A, Chen B, Xu Q, Zhu J, Zhang Z, Chen X, et al. PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease. PLOS Neglected Tropical Diseases. 2026. doi:10.1371/journal.pntd.0014483

BibTeX
@article{Tuohetali2026,
  author = {Tuohetali, Ayinula and Chen, Bei and Xu, Qinwei and Zhu, Jiang and Zhang, Zhenping and Chen, Xia and Ma, Yixueying and Kuerban, Kadierya and Aimulajiang, Kalibixiati and Gao, Huijing},
  title = {PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2026},
  doi = {10.1371/journal.pntd.0014483}
}
Kostenlos starten →